- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Macular oedema secondary to retinal vein occlusion (RVO)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Faricimab – March 2025
Faricimab; Solution for intravitreal injection 21 mg in 0.175 mL (120 mg per mL) pre-filled syringe; Vabysmo®
Last updated
12 March 2025